Search results for "Coronavirus"
No tested biomarkers successfully identified postacute sequelae of SARS-CoV-2
The RECOVER study compared 25 biomarkers in patients who had no lingering symptoms of COVID-19 and those who had at least 12 postacute sequelae symptoms and found no significant differences between the groups.
https://immattersacp.org/weekly/archives/2024/08/13/4.htm
13 Aug 2024
Latest COVID-19 research focuses on PASC, prophylaxis, pregnancy
Postacute sequelae of COVID-19 (PASC) rates dropped with recent variants, one study showed, while an industry trial of postexposure prophylaxis found no effect, and a third study found no risk of congenital anomalies associated with infection or vaccination in the first trimester of pregnancy.
https://immattersacp.org/weekly/archives/2024/07/23/4.htm
23 Jul 2024
COVID-19 vaccine side effects associated with greater antibody response, study finds
The association between worse symptoms after vaccination and higher antibody levels against SARS-CoV-2 in subsequent months could be used to encourage reluctant patients to be vaccinated, study authors suggested.
https://immattersacp.org/weekly/archives/2024/06/11/2.htm
11 Jun 2024
New COVID-19 vaccine recommendations, data on after-effects of infection
The CDC recommended another COVID-19 booster for older patients and ended five-day isolation guidelines, while studies showed that COVID-19 infection was associated with a small cognitive decline and an increase in risk for autoimmune inflammatory rheumatic diseases.
https://immattersacp.org/weekly/archives/2024/03/05/4.htm
5 Mar 2024
One-fifth of COVID-19 patients taking nirmatrelvir-ritonavir had viral rebound
A small observational study of ambulatory patients with COVID-19 found that 1.8% of untreated patients tested positive again after testing negative, compared to 20.8% of those who took five days of nirmatrelvir-ritonavir.
https://immattersacp.org/weekly/archives/2023/11/14/4.htm
14 Nov 2023
Latest COVID-19 studies show need for repeat rapid testing, targeting of antiviral prescriptions
Viral load of SARS-CoV-2 doesn't peak until the fourth day of symptoms, one study found, while other research only saw an effect of nirmatrelvir/ritonavir on death and hospitalization among those who were moderately or severely immunocompromised, not in other high-risk groups.
https://immattersacp.org/weekly/archives/2023/10/03/2.htm
3 Oct 2023
CDC recommends COVID-19 booster; ACP updates practice points for outpatient treatment
Everyone ages 6 months and older should get an updated COVID-19 vaccine to protect against a potentially serious outbreak this fall and winter, the CDC said last week.
https://immattersacp.org/weekly/archives/2023/09/19/1.htm
19 Sep 2023
PASC defined, analyzed by latest COVID-19 studies
Two recent studies focused on postacute sequelae of SARS-CoV-2 (PASC), while another assessed the effectiveness of nirmatrelvir-ritonavir and molnupiravir in reducing morbidity and mortality from COVID-19.
https://immattersacp.org/weekly/archives/2023/06/06/2.htm
6 Jun 2023
ACP, Annals of Internal Medicine host forum on the end of the COVID-19 Public Health Emergency
A full recording of “COVID-19 Is No Longer a Public Health Emergency: Implications for Patients and Clinicians” is available online.
https://immattersacp.org/weekly/archives/2023/05/23/6.htm
23 May 2023
CBT improved severe fatigue after COVID-19, Dutch trial finds
After randomization, patients with severe fatigue three to 12 months after COVID-19 infection benefited from cognitive behavioral therapy (CBT) compared to usual care.
https://immattersacp.org/weekly/archives/2023/05/16/2.htm
16 May 2023
Register now for ACP and Annals of Internal Medicine's forum on the end of the COVID-19 Public Health Emergency
The virtual live event will be held on May 19 from 3:30 to 5 p.m. ET.
https://immattersacp.org/weekly/archives/2023/05/09/5.htm
9 May 2023
Studies look at effectiveness of bivalent booster, fluvoxamine plus inhaled budesonide for COVID-19
After four weeks, bivalent booster vaccines were 47.5% effective against hospitalization or death from COVID-19, a study in North Carolina found, while a Brazilian trial showed that fluvoxamine plus inhaled budesonide significantly reduced the risk of progression to severe disease among high-risk patients with symptomatic COVID-19.
https://immattersacp.org/weekly/archives/2023/04/18/2.htm
18 Apr 2023
COVID-19 rebound occurs with or without antivirals, doesn't affect outcomes, studies find
Rebound of both COVID-19 symptoms and viral load was rare in untreated, unvaccinated outpatients, one study showed, while another found similar rates of viral rebound in patients treated with nirmatrelvir-ritonavir, molnupiravir, or neither antiviral.
https://immattersacp.org/weekly/archives/2023/02/21/2.htm
21 Feb 2023
CDC and FDA weigh in on safety of bivalent vaccine; research examines COVID-19 sequelae, omicron variants
The CDC and FDA said an observed association of ischemic stroke with the Pfizer-BioNTech bivalent booster is very unlikely to represent a true clinical risk. New studies reported on symptoms a year after mild COVID-19 and estimated protection against the omicron variants.
https://immattersacp.org/weekly/archives/2023/01/24/2.htm
24 Jan 2023
New ACP living practice points, mortality data on COVID-19
The College offered recommendations on outpatient COVID-19 treatments. Three studies looked at shifts in mortality from COVID-19 at different times and places. An international study compared infections in health care workers with medical masks versus N95s.
https://immattersacp.org/weekly/archives/2022/11/29/2.htm
29 Nov 2022
Monoclonal antibodies appear safe as COVID-19 treatment during pregnancy
Pregnant patients who received monoclonal antibody treatments had no higher risk for adverse obstetric events but also no significant improvement on COVID-19-related outcomes, a retrospective study found.
https://immattersacp.org/weekly/archives/2022/11/15/2.htm
15 Nov 2022
Frequency of COVID-19 rebound debated in research, ACP/Annals forum
Two letters reported on SARS-CoV-2 viral rebound among patients taking nirmatrelvir-ritonavir. The latest ACP and Annals of Internal Medicine forum brought experts together to discuss this and other clinical challenges in COVID-19 prevention and management on Wednesday, Sept. 7.
https://immattersacp.org/weekly/archives/2022/09/13/2.htm
13 Sep 2022
New COVID-19 boosters authorized and recommended
The CDC has recommended the new formulations of the mRNA vaccines, targeted at the BA.4 and BA.5 lineages of the omicron variant, for adults and adolescents who last received a COVID-19 shot at least two months ago.
https://immattersacp.org/weekly/archives/2022/09/06/2.htm
6 Sep 2022
Register now for ACP and Annals of Internal Medicine's COVID-19 Forum X: Current Clinical Challenges in COVID-19 Prevention and Management
During the Sept. 7 virtual live event, a panel of experts will discuss current methods for preventing and managing SARS-CoV-2 infection.
https://immattersacp.org/weekly/archives/2022/08/30/4.htm
30 Aug 2022
Latest COVID-19 research on VTE risk, treatment with metformin, ivermectin, fluvoxamine
Unvaccinated patients may have higher risk of venous thromboembolism (VTE) when mildly ill, one study found, while another showed no effect from metformin, ivermectin, or fluvoxamine. Research supported the safety of the mRNA vaccines, and the NIH updated its treatment guidelines.
https://immattersacp.org/weekly/archives/2022/08/23/4.htm
23 Aug 2022